Urinary Catheters Market: Growing prevalence of urinary incontinence

 The growing prevalence of urinary incontinence, an increasing number of surgical procedures across the globe, high incidence of prostate cancer, and the favorable reimbursement scenario are the major factors driving the growth of this market.

The global urinary catheters market size is projected to reach USD 2.6 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 5.5% during the forecast period.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132934629

Scope of the Report

This report categorizes the urinary catheters market into the following segments and subsegments:

By Product

• Indwelling Catheters
• Intermittent Catheters
• External Catheters

By Type

• Coated Catheters
• Uncoated Catheters 

By Usage

• Male Urinary Catheters
• Female Urinary Catheters 

By Application

• Urinary Incontinence
• General Surgery
• Benign Prostatic Hyperplasia
• Other Applications (spinal cord injuries, spina bifida, multiple sclerosis, and Parkinson’s disease)

By End-User

• Hospitals
• Long-Term Care Facilities
• Other End Users (emergency clinics and physicians’ offices)

By Region

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• RoE
• Asia Pacific
• Japan
• China
• India
• Rest of Asia Pacific
• Rest of the World

Market Segmentation :

Based on products, the global market is segmented into indwelling catheters, intermittent catheters, and external catheters. Indwelling catheters accounted for the largest share of the market in 2019. These catheters are also widely used in high-acuity patient units, with critical care and intensive care units registering the highest usage of indwelling catheters. Growth in this market is largely driven by the cost-efficiency and high availability of indwelling catheters in the market.

By catheter type, the global market is segmented into coated and uncoated catheters. Coated catheters accounted for the largest share of the market in 2019. This segment is also expected to register the highest CAGR during the forecast period. Growth in this market is mainly driven by the various advantages associated with coated catheters, such as easier, more comfortable insertion, low risk of catheter-associated urinary tract infection, reduced risk of urethral damage, and improved patient satisfaction.

Regional Analysis: -

The market is segmented into four major regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America was the largest regional market for urinary catheters in 2019. The large share of North America in this market can be attributed to the favorable reimbursement scenario and the rising volume of surgeries in the region. However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The high growth in this market can be attributed to the growing healthcare spending in emerging Asian countries, rising prevalence of urinary incontinence, and the large target patient population in the region.

Inquiry Before Buying:- https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=132934629

Top Key Players:-

The global urinary catheters market is highly consolidated. The prominent players operating in this market include B. Braun Melsungen AG (Germany), Boston Scientific Corporation (US), Coloplast Ltd. (Denmark), ConvaTec Inc. (UK), Becton, Dickinson and Company (US), Cardinal Health (US), Teleflex Incorporated (US), Wellspect HealthCare (US), and Cook Medical (US). Other players include Asid Bonz GmbH (Germany), Degania Silicone Ltd. (Israel), Bactiguard (Sweden), Medical Technologies of Georgia (US), ROCAMED (Monaco), Well Lead Medical Co., Ltd. (China), Go Medical Industries Pty Ltd. (Australia), Cure Medical, LLC, Amsino International, Inc. (US), Urocare Products, Inc. (US), J and M Urinary Catheters LLC. (US), CompactCath (US), Hunter Urology (England), MANFRED SAUER GMBH (Germany), and Ribbel International Limited (India).

Benign Prostatic Hyperplasia Treatment Market: Increasing prevalence of benign prostatic hyperplasia

 

Benign prostatic hyperplasia (BPH) is a common condition among older men where the prostate gland grows in size and puts pressure on the urethra, leading to difficulty urinating. BPH is a progressive condition, and if left untreated, it can cause severe urinary symptoms, bladder damage, and even kidney damage.

The growth of Benign Prostatic Hyperplasia Treatment Market is driven by the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment.

The Benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. 

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198000374

Scope of the Report

This research report categorizes the benign prostatic hyperplasia treatment market into the following segments and subsegments:

Benign Prostatic Hyperplasia Treatment Market by Type

  Drug Treatment

• Alpha Blockers
• Alfuzosin
• Doxazosin
• Tamsulosin
• Silodosin
• Other Alpha Blockers
• 5-Aplha Reductase Inhibitors
• Finasteride
• Dutasteride
• Other Drug Classes

  Surgical Treatment

• Transurethral Resection of the Prostate (TURP)
• Transurethral Microwave Thermotherapy (TUMT)
• Transurethral Needle Ablation of the Prostate (TUNA)
• Laser Therapy
• Prostatic Stenting
• UroLift Therapy
• Rezûm Therapy
• Other Surgeries

Benign Prostatic Hyperplasia Treatment Market, by Region

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific

Market Segmentation:-

Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.

Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.

Regional Analysis:

On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.

Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=198000374

Recent Developments

·         In 2021, In January 2021, PHAREX Health Corporation in partnership with the Philippine Urological Association (PUA), launched Pharex Tamsulosin for BPH treatment.

·         In 2020, UroLift launched Advanced Tissue Control (ATC) System

·         In 2020, Asahi Kasei Pharma obtained Chinese approval for Flivas (naftopidil).

·         In 2019, Alembic received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Silodosin Capsules 4 mg and 8 mg

·         In 2018, NxThera’s Rezûm system, a minimally invasive therapy (MIT) for patients with BPH, was included under Boston’s Urology and Pelvic Health business.

·         In 2017, Eli Lilly and Company entered into a settlement agreement with generic companies to resolve pending patent litigation.

 

Top Key Players: -

The major players operating in this market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Teleflex Incorporated (US), Olympus Corporation (Japan), GlaxoSmithKline PLC (UK), Eli Lilly (US), Pfizer, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation (US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada). Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ SE & Co. KG (Germany), and SRS Medical (US).

Conclusion

In conclusion, the global market for BPH treatment is expected to grow in the coming years, driven by the increasing prevalence of BPH among the aging population and the demand for minimally invasive procedures. With the advent of new and innovative treatment options, the BPH treatment market is poised for further growth and development in the future.

 

Blood Screening Market worth $3.8 billion by 2026 - Exclusive Report by MarketsandMarkets™

 The demand for donated blood is rising because of advancements in healthcare systems and the availability of and the need for sophisticated surgical procedures, such as cardiovascular & transplant surgery, trauma care, and therapy for cancer and blood diseases. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the market.

The global Blood screening market is projected to reach USD 3.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 8.4%. 

Download PDF Brochure:-  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042

Scope of the Report

This report categorizes the blood screening market into the following segments and subsegments:

By Product & Service

• Reagents & Kits
• NAT Reagents & Kits
• Enzymes & Polymerases
• Standards & Controls
• Probes & Primers
• Buffers, Nucleotides, and Solutions
• Labeling & Detection Reagents
• ELISA Reagents & Kits
• Immunosorbents
• Controls
• Conjugates
• Substrates
• Sample Diluents & Wash Solutions
• Other Reagents & Kits
• Instruments
• Rental Purchase
• Outright Purchase
• Software & Services

By Technology

• Nucleic Acid Test
• Transcription-mediated Amplification
• Real-time PCR
• ELISA
• Chemiluminescent Immunoassays
• Fluorescent  Immunoassays
• Colorimetric Immunoassays
• Rapid Tests
• Western Blot Assays
• Next-generation Sequencing

By End User

• Blood Banks
• Hospitals

By Region

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• Rest of Asia Pacific
• Latin America
• Australia
• Rest of Latin America
• Middle East & Africa

Market Segmentation: -

The blood screening market is segmented into reagents & kits, instruments, and software & services. The reagents & kits accounted for the largest share of the market in 2020, mainly due to repeated use of reagents & kits in blood screening procedures due to the rising blood transfusion procedures, and the high consumption.

The blood screening market is segmented into nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). In 2020, the nucleic acid test (NAT) segment accounted for the largest share of the market. Factors such as the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies and increasing number of blood donations.

Based on end users, the blood screening market is segmented into blood banks and hospitals. In 2020, the blood banks segment accounted for the largest share of the market. The growing number of organ transplantation surgeries is driving the growth of this segment, and the increasing demand for donated blood.

Regional Analysis:

The global market is segmented into five major regions—north America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the market. The North American market growth can be attributed to the increasing healthcare spending, increasing prevalence of chronic disorders, and the highly developed healthcare system in the US and Canada.

Request Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=267747042

Top key Players:-

The major players operating in this blood screening market are Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US), DiaSorin (Italy), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA (Germany), PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), and Cepheid (US).